Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Jupiter to buy UK non-profits assets manager CCLA for £100m

(Sharecast News) - Jupiter Fund Management said on Thursday that it has agreed to buy CCLA - the UK's largest asset manager focused on serving non-profit organisations - for £100m. CCLA manages more than £15bn in assets under management on behalf of charities, religious institutions and local authorities.

Jupiter said the deal is "highly compelling" from strategic, cultural and financial perspectives, delivering progress against multiple objectives.

It said the acquisition marks a significant step forward in delivering on its key strategic objective of increasing scale, specifically within its home market of the UK. It also opens up a new client channel and provides complementary investment expertise "with a high degree of cultural alignment".

The acquisition is expected to be materially accretive to management fee earnings per Jupiter share from day one, with further accretion over time as synergies are delivered.

The initial target for run-rate cost synergies on a fully integrated basis is at least £16m a year and this target is expected to be fully realised by the end of 2027.

Chief executive Matthew Beesley said: "This Acquisition helps us to increase scale in our home market of the UK, where Jupiter is already a leading player, without any disruption to our existing clients. It opens up a new client segment for us, broadening our appeal to a range of charitable and religious institutions, both in the UK and internationally, while also allowing us to expand our existing presence in the UK Local Authority sector.

"Importantly, Jupiter and CCLA share a common set of values, and each has a client-centric culture and history of focusing on active and differentiated investment solutions."

The acquisition will be funded entirely from existing balance sheet cash resources and no new equity or debt will be issued.

At 0945 BST, the shares were up 12% at 121.40p.

Dan Coatsworth, investment analyst at AJ Bell, said: "The latest in a long line of consolidation within the asset management industry sees CCLA being bought by Jupiter.

"This looks to be one of these deals that makes a lot of sense given the lack of crossover across the fund range, with CCLA having a clear specialism in the ethical investment and stewardship space.

"Jupiter has a history with this type of investing given its long-standing Ecology fund. However, its capability has always looked light in an area that will likely become mainstream over time despite the recent challenges that have come from responsible investment.

"The acquisition of CCLA also diversifies the client base of Jupiter given the heritage of the target with charity, local authority and Church of England investors, which makes the deal look sensible from a business perspective. Jupiter will need to convince these clients that it will continue to hold CCLA's core principles at the heart of its investment approach.

"With little crossover of funds, Jupiter will be looking to see what cost savings can be made behind the scenes as it looks to increase scale to tackle the challenges that passive investing brings to those pursuing an active led approach. Jupiter is not alone in this regard and therefore it seems highly likely we see further M&A activity in the asset management sector."

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.